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Abstract
Background and purpose Morphologic magnetic resonance imaging (MRI) for characterization of salivary gland tumors 
has limited utility, and the use of perfusion MRI data in the clinical setting is controversial. We examined the potential of 
tissue-normalized dynamic contrast-enhanced (DCE) MRI pharmacokinetic parameters of salivary gland tumors as imaging 
biomarkers for characterization and differentiation between benign and malignant lesions.
Materials and methods DCE-MR images acquired from 60 patients with parotid and submandibular gland tumors were 
retrospectively reviewed. Pharmacokinetic parameters as transfer constant (Ktrans), rate constant (Kep), extracellular space 
volume (Ve), fractional plasma volume (Vp), and AEC (area of all times enhancement curve) were measured on both the lesion 
and the normal contralateral salivary gland parenchyma. Lesion/parenchyma ratio (L/P) for each parameter was calculated.
Results Five groups of lesions were identified (reference: histopathology): pleomorphic adenomas(n = 20), Warthin 
tumors(n = 16), other benign entities(n = 4), non-Hodgkin lymphomas(n = 4), and malignancies(n = 16). Significant differ-
ences were seen for mean values of L/PKtrans (higher in malignancies), L/PKep (lower in adenomas than Warthin tumors), 
L/PVe (lower in Warthin tumors and lymphomas), L/PVp (higher in Warthin tumors and malignancies than adenomas), and 
L/PAEC (higher in malignancies). Significant differences were found between benign and malignant (non-lymphoprolif-
erative) lesions in mean value of L/PKtrans (0.485 and 1.581), L/PVp (1.288 and 2.834), and L/PAEC (0.682 and 1.910). 
ROC analysis demonstrated the highest AUC (0.96) for L/PAEC, with sensitivity and specificity for malignancy of 93.8% 
and 97.5% (cutoff value = 1.038).
Conclusion Lesion/parenchyma ratio of DCE-MRI pharmacokinetic data could be helpful for recognizing the principal types 
of salivary gland tumors; L/PAEC seems a valuable biomarker for differentiating benign from malignant tumors.
Keywords Salivary gland tumors · Dynamic contrast-enhanced MRI · Pharmacokinetic analysis · Imaging biomarkers · 
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Introduction
In patients with salivary gland tumors, the distinction 
between benign and malignant neoplasm is critical, since 
the latter demands more aggressive intervention [1]. 
Magnetic resonance imaging (MRI) represents the pri-
mary preoperative diagnostic modality in patients with 
salivary gland tumors. Routine pre- and post-contrast MR 
sequences allow determining the extent of disease (locali-
zation of the primary tumor and regional lymph nodes 
involvement) and evaluating morphologic features of the 
lesion such as dimensions, shape, margins, and the pres-
ence of cystic/necrosis/fluid areas [2]. Still, various benign 
and malignant tumors often show non-specific imaging 
findings and overlapping morphologic characteristics 
[3–6], so differentiation between the two groups is gener-
ally tricky.
Current clinical guidelines advise obtaining a lesion sam-
ple by the use of fine-needle aspiration cytology (FNAC) or 
ultrasound-guided core needle biopsy (CNB) [1]. However, 
FNAC presents limited sensitivity and a high number of 
non-diagnostic samples [7] while CNB, despite the diag-
nostic superiority [8], is still not considered the reference 
standard due to invasiveness, possible false negatives, and 
risk of tumor seeding [9]. For these reasons, many efforts 
are recently put into determining if multiparametric and 
advanced MR sequences such as diffusion-weighted imag-
ing (DwI) and dynamic contrast-enhanced (DCE) imaging 
could have a role in characterizing salivary gland tumors 
[10–13] and differentiating benign from malignant lesions 
[12–15], with various results.
DCE-MRI provides biomarkers of tissue perfusion with 
proven utility in oncologic imaging and has been widely 
employed for diagnosis, prognosis, and therapy monitoring 
of cancer. Nevertheless, obtaining reproducible and clini-
cally feasible imaging biomarkers from perfusion and per-
meability analysis is still a challenge because conspicuous 
repeatability and reproducibility data are lacking. Sources 
of variables in quantitative DCE-MRI analysis are various 
[16], and measured perfusion parameters broadly vary across 
different research sites, preventing data comparison in multi-
institutional clinical trials. As a result, in routine clinical 
practice, DCE-MRI is prevalently analyzed only qualita-
tively, with possible operator-dependent different results. 
To overcome these problems, it could be useful having a 
specific per-patient reference parameter such as the stand-
ard reference tissue. The ratio of DCE-MR pharmacokinetic 
parameters between a lesion and the standard reference tis-
sue could potentially mitigate the variability linked to exter-
nal factors and provide a more reliable representation of the 
intrinsic microvascularity and interstitial changes occurring 
in the different lesions with respect to the normal tissue [17].
Therefore, the purpose of this study was to examine the 
potential of tissue-normalized DCE-MRI pharmacokinetic 
parameters of salivary gland tumors as imaging biomarkers 




Our institutional review board approved this retrospective 
study (protocol number 2042/2019). Informed consent was 
obtained from all patients. We reviewed MR imaging per-
formed from January 2015 to November 2018 in 72 con-
secutive patients with known (from clinical examination and 
previous ultrasound/CT imaging) parotid or submandibular 
gland tumors. All of these tumors were characterized both 
by histology analysis derived from ultrasound-guided CNB 
and histopathological confirmation when surgically excised. 
The other inclusion criteria of this study were: the maximum 
diameter of the lesion greater than 1 cm with the presence of 
enough non-cystic areas (at least 50% of the entire volume 
of the lesion); the availability of DCE-MRI images without 
significant susceptibility or motion artifacts; patients had 
no previous radiation treatment on head and neck district 
nor known chronic inflammatory salivary gland disease (i.e., 
Sjogren’s disease). Consequently, we excluded eight patients 
due to low image quality related to motion artifacts and two 
patients because of the predominant cystic component of 
the tumors. Two patients with bilateral tumors were also 
excluded from the study.
Resulting 60 lesions were then categorized into five dif-
ferent groups based on histopathology results: pleomorphic 
adenoma, Warthin tumors, other benign entities, non-Hodg-
kin lymphoma, and malignancies.
Conventional and DCE‑MR imaging acquisitions
All MRI studies were performed by using a 1.5-T MR scan-
ner (MAGNETOM Aera, Siemens Healthcare, Erlangen, 
Germany) with a dedicated head coil. Our protocol (Table 1) 
included morphologic imaging constituted by 3D-T1w and 
3D-FS T2w sequences, axial TSE T2w imaging, and DwI. 
For DCE acquisition, we used a 3D fast spoiled gradient 
recalled echo T1w imaging obtained after intravenous 
administration of 0.1 mmol/kg bodyweight of Gadobutrol 
(Gadovist, Bayer Schering Pharma AG) at an injection rate 
of 3 ml/s, followed by a 20-ml saline flush. After contrast 
injection, at least 50 phases were acquired, covering more 
than 4 min with a temporal resolution of 5 s. DCE acquisi-
tions were preceded by a variable flip angle (FA 5° and 15°) 
series, for pre-contrast agent native tissue T1 mapping.
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Post‑processing of DCE‑MRI images
Post-processing of acquired DCE-MR images was per-
formed by using the application MR Permeability avail-
able inside the commercial software IntelliSpace Portal 
v.8.0 (Philips Healthcare, Best, The Netherlands). DCE-
MRI data were elaborated in distinctive steps, according 
to what has been recommended by QIBA (Quantitative 
Imaging Biomarker Alliance) initiative [18]:
• Generating a native tissue T1 map using the variable 
flip angle data
• Applying time-series motion correction to the dynamic 
data
• Converting DCE-MRI signal intensity data, SI(t), to 
gadolinium concentration ([Gd](t))
• Calculating a vascular input function (VIF)
The pharmacokinetic calculation was done on a pixel-
by-pixel basis using a 2-compartment model, based on the 
extended Tofts model (ETM) [19]:
where:
C(t): Contrast concentration in tissue.
Vp: The fractional value of blood plasma (also referred 
to as volume fraction of plasma space).
Ca(t): VIF (contrast concentration in feeding artery).
C(t) = Vp ∗ Ca(t) + Ktrans ∗ e−tKep ∗ Ca(t)
Ktrans: Transfer constant between blood plasma and 
extravascular extracellular blood space (EES).
Kep: Rate constant between EES and blood plasma 
(Ktrans/Ve).
We chose to apply a model-based VIF with a fixed bi-
exponential shape related to the type and dose of injected 
contrast media (0.1 mmol/kg of Gadobutrol), the duration 
of contrast injection (5 to 10 s), and an average hematocrit 
value of 45%. Then, we carried out a pixel-by-pixel analysis 
to generate color-coded maps of Ktrans, Kep, Ve (fractional 
EES volume), Vp, and AEC (area of all times enhancement 
curve) for the whole volume.
Regions of interest (ROI) selection and extraction 
of DCE parameters
Morphologic and DCE-MR images were reviewed in con-
sensus by two radiologists (F.M. and G.V) with 12 and five 
years of experience in head and neck imaging, blinded to 
the histopathology results. An ROI encompassing as much 
of the tumor area as possible was manually drawn, excluding 
large cystic or necrotic areas. Then, preferably on the same 
slice of the acquisition volume, another ROI with compa-
rable area size was drawn inside the contralateral visually 
normal salivary gland parenchyma, excluding large vessels, 
such as the retromandibular vein, and normal intraparenchy-
mal lymph nodes.
Table 1  Imaging Protocol
TR Time of repetition; TE time of echo; FA flip angle; VFA variable flip angle; FOV field of view; ST slice thickness; TA time of acquisition; 
GRAPPA generalized autocalibrating partially parallel acquisition; SPACE sampling perfection with application optimized contrasts using differ-
ent flip angle evolution; FS fat saturation; DWI diffusion-weighted imaging; EPI echo planar imaging ; SPAIR spectral selection attenuated inver-
sion recovery; VIBE volumetric interpolated breath hold examination; DCE dynamic contrast enhanced
Parameters SPACE T1w SPACE T2w FS TSE T2w DWI EPI SPAIR VIBE Dixon T1w DCE
TR (ms) 500 3000 5050 4400 10 4.65
TE (ms) 7.2 380 117 54 TE 1: 2.39 TE 2: 4.47 1.66
FA (degree) VFA VFA 90°-150° 90° 10° 30° (two preliminary 
sequences with 5° and 
15° FA)
Acquisition matrix 230 × 256 230 × 256 261 × 384 118 × 148 240 × 240 139 × 192
Recon matrix 230 × 256 230 × 256 261 × 384 118 × 148 240 × 240 139 × 192
FOV 229 × 229 229 × 229 210 × 190 240 × 240 225 × 225 250 × 226
ST (mm) 0.9 0.9 3 3 0.9 3.5
Distance factor // // 30% (0.9 mm) 30%(0.9 mm) // //
Voxel dimensions (mm) 0.9 × 0.9× 0.9 0.9 × 0.9 × 0.9 0.5 × 0.5 × 3 1.6 × 1.6 × 3.0 0.9 × 0.9 × 0.9 1.3 × 1.3 × 3.5
b values // // // 50–100-200–800 // //
Temporal resolution (s) // // // // // 5 (50 volumes)
TA (min) 5:47 5:56 2:23 7:07 4:37 4:17
GRAPPA 2 2 2 3 // 3
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Since the lesion and the normal salivary gland paren-
chyma were well delineated on contrast-enhanced T1w 
images, we used the dynamic series of DCE acquisition for 
ROIs drawing. We created summation images (obtained by 
adding together images acquired on the dynamic series for 
each slice location), and we used average images to per-
form the segmentation (Fig. 1a). As these segmentations 
were registered in the dynamic set, we used them to directly 
extract lesion- and parenchyma-based parameters from para-
metric maps. Visual analysis of the time–signal intensity 
curve (TIC) resulting from each segmentation was carried 
out for quality assessment (Fig. 1a); when a non-viable curve 
occurred, the segmentation was repeated. We also performed 
a visual assessment of the generated color-coded maps of 
Ktrans, Kep, Ve, Vp, and AEC (Fig. 1b).
We finally obtained the lesion/parenchyma ratio (L/P) of 
the DCE parameters (L/P Ktrans, L/P Kep, L/P Ve, L/P Vp, 
and L/P AEC) by dividing the mean values measured in the 
two ROIs for each patient.
Statistical analysis
Because of the small sample size of the five groups and the 
non-normal distribution of the data, the Kruskal–Wallis H 
test was performed to assess whether there were any sta-
tistically significant differences between the means of the 
five different groups of lesions in the calculated parameters 
(L/P Ktrans, L/P Kep, L/P Ve, L/P Vp, L/P AEC). Dunn’s 
pairwise test (using the Bonferroni correction) was then run 
to confirm the differences that occurred between the groups.
Then, t test and receiver operator characteristics (ROC) 
analysis were performed to find out the performance of the 
lesion/parenchyma ratio of DCE parameters for the distinc-
tion between the benign lesions (including pleomorphic 
adenoma, Warthin tumors, and the other benign entities) 
and the malignancies (excluding non-Hodgkin lymphomas). 
We finally performed the discriminant analysis for assess-
ing the performance of the lesion/parenchyma ratio of DCE 
parameters in isolation or in combination for discriminating 
between benign and malignant lesions. All statistical analy-
ses were performed by using SPSS statistic software (v.25; 
IBM SPSS, Chicago, Ill.).
Results
Resulting 60 lesions were then categorized into five differ-
ent groups based on histopathology results: pleomorphic 
adenoma (n = 20), Warthin tumors (n = 16), other benign 
entities (n = 4), non-Hodgkin lymphoma (n = 4), and malig-
nancies (n = 16). Of 60 patients, there were finally 40 benign 
tumors, 16 malignancies, and 4 non-Hodgkin lymphomas. 
Origin, maximum diameter, and histopathological diagnosis 
of the tumors are shown in Table 2. Descriptive analysis for 
L/P Ktrans, L/P Kep, L/P Ve, L/P Vp, and L/P AEC in the 
five groups is shown in Table 3. Kruskal–Wallis and Dunn’s 
pairwise tests showed the following statistically significant 
differences among groups. The group of malignancies pre-
sented higher mean L/P Ktrans value than the groups of 
pleomorphic adenomas (1.581 versus 0.440, P < 0.001), 
Warthin tumors (0.510, P = 0.001), and lymphomas (0.366, 
P = 0.006). The group of pleomorphic adenomas presented 
lower mean L/P Kep values than the groups of Warthin 
tumors (0.323 vs. 0.861, P < 0.001), and malignancies 
(0.659, P = 0.05). Lower mean L/P Ve values were found 
in Warthin tumors respect to pleomorphic adenomas (0.652 
vs. 1.868, P = 0.001) and malignancies (2.524, P < 0.001); 
lymphomas also had lower mean L/P Ve than malignan-
cies (0.479 vs. 2.524, P = 0.001) and pleomorphic adeno-
mas (P = 0.025). Differences in mean L/P Vp were found 
when comparing pleomorphic adenomas to Warthin tumors 
(0.418 vs. 2.206, P < 0.001) and malignancies (2.834, 
P < 0.001); lymphomas also had lower mean L/P Vp than 
Warthin tumors (0.317 vs. 2.206, P = 0.012) and malignan-
cies (P = 0.025). Finally, mean L/P AEC values were higher 
in malignancies respect to pleomorphic adenomas (1.910 vs 
0,584, P < 0.001), Warthin tumors (0.745, P < 0.001), and 
lymphomas (0.342, P = 0.002). In Table 4, a summary of 
types of lesions with L/P ratio higher or lower than 1.0 is 
described.
After excluding the n = 4 lymphomas from the analysis, 
we found statistically significant differences between benign 
and malignant lesions in mean value of L/P Ktrans (respec-
tively, 0.485 and 1.581, P = 0.001), L/P Vp (1.288 and 
2.834, P = 0.006), and L/P AEC (0.682 and 1.910, P < 0.001) 
(Table 5 and Fig. 2). ROC analysis demonstrated an area 
under the curve, respectively, of 0.933 for L/P Ktrans and 
0.955 for L/P AEC (Fig. 3). By applying the cutoff L/P AEC 
value of 1.038, sensitivity and specificity in discriminating 
malignant from benign lesions were, respectively, 93.8% 
and 97.5%. Finally, discriminant analysis with a stepwise 
approach demonstrated that the L/P AEC alone is better than 
any other combination of parametric ratios in differentiating 
malignancy from a benign lesion (Figs. 4, 5).
Discussion
This study investigated the potential use of the lesion/paren-
chyma ratio of DCE-MRI pharmacokinetic parameters for 
characterization and differentiation between benign and 
malignant salivary gland tumors. DCE-MRI, especially 
when acquired using a high temporal resolution (< 6 s per 
volume acquisition), is a useful technique to noninvasively 
disclose the changes in microvascular perfusion and extra-
cellular space volume of tumors with respect to standard 
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Fig. 1  57-year-old woman 
with Warthin tumor of the left 
parotid gland (white arrow). 
ROI selection and extraction 
of DCE-MRI parametric maps. 
Figure a demonstrates the delin-
eation of the lesion (ROI 1–blue 
line), and the normal contralat-
eral parotid parenchyma (ROI 
2–orange line) on the dynamic 
series of DCE acquisition; 
corresponding time–signal 
intensity (TIC) curves of the 
two ROIs are shown below. 
Matching color-coded maps of 
Ktrans, Ve, Vp, and AEC are 
displayed in Fig. b. Lesion/
parenchyma ratio (L/P) values 
found for this case were: L/P 
Ktrans = 0.59, L/P Kep = 1.05, 
L/P Ve = 0.57, L/P Vp = 3.42, 
and L/P AEC = 0.83
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origin tissue [20]. Parotid, submandibular, and other sali-
vary glands are constituted by a normally variegated tissue, 
mainly composed of serous and mucinous acini, an onco-
cytic epithelium forming intercalated and striated ducts and 
surrounded by myoepithelial cells, some sebaceous ele-
ments, adipose cells (more abundant in the parotids with 
a ratio of adipose to glandular tissue up to 1:1), and higher 
microvascular density than adjacent soft tissues; inside the 
parotids there are also about ten lymph nodes [21]. As a 
result, normal salivary gland parenchyma usually presents 
prominent vascular perfusion with a TIC curve composed 
by an early peak of contrast enhancement (40 to 60 s after 
Table 2  Summary of salivary lesions and patients characteristics
Histology (number of lesions) Site (number of lesions) Patient sex Patient age (range) Diameter in cm (range)
Pleomorphic adenoma (20) Parotid (17) Submandibular (3) 13 female; 7 male 47.8 (27–76) 2.6 (1–4.7)
Warthin tumor (16) Parotid (16) 5 female; 11 male 64 (54–71) 1.8 (1.5–2.5)
Other benign tumors (total = 4): Parotid (4) 2 female; 2 male 72.2 (68–80) 2.4 (1.4–3.5)
 Myoepithelioma (2) Parotid (1) 1 female; 1 male 75 (70–80) 2.85 (2.2–3.5)
 Oncocytoma (1) Parotid (1) 1 female 71 1.4
 Basal cell adenoma (1) Parotid (1) 1 male 68 2.4
Non-Hodgkin lymphoma (4) Parotid (4) 2 female; 2 male 65 (60–68) 2.9 (2.2–3.6)
Malignant lesions (total = 16): Parotid (13) Submandibular (4) 9 female; 7 male 60.5 (39–75) 2.7 (1.2–6)
 Cystic adenoid carcinoma (3) Parotid (1) Submandibular (2) 2 female; 1 male 65.7 (63–70) 2.5 (2–2.8)
 Mucoepidermoid carcinoma (3) Parotid (1) Submandibular (2) 1 female; 2 male 53.7 (50–59) 1.9 (1.2–2.5)
 Carcinoma ex pl. adenoma (3) Parotid (3) 3 female 49.3 (39–60) 2.5 (1.3–3.1)
 Salivary duct adenocarcinoma (1) Parotid (1) 1 male 71 2.9
 Basal cell adenocarcinoma (1) Parotid 1 female 70 1.7
 Squamous cell carcinoma (2) Parotid (2) 1 female; 1 male 72 (69–75) 2.5 (2–3)
 Undifferentiated carcinoma (2) Parotid (2) 2 male 58 3.7 (2.9–4.5)
 Clear cell carcinoma metastasis (1) Parotid 1 female 60 6
Table 3  Descriptive analysis for L/P Ktrans, L/P Kep, L/P Ve, L/P Vp, and L/P AEC in the five main groups of lesions
Data are mean values ± standard deviation
* and ** refer to correlated significant different (< 0.05) values for each parameter (in bold the highest or the lowest)
Ktrans transfer constant between blood plasma and extravascular extracellular blood space (EES); Kep rate constant between EES and blood 
plasma (Ktrans/Ve); Ve fractional EES volume; Vp fractional plasma volume; AEC area of all times enhancement curve
Histology L/P Ktrans L/P Kep L/P Ve L/P Vp L/P AEC
Pleomorphic adenoma (n = 20) 0.440 ± 0.249* 0.323 ± 0.252* 1.868 ± 1.384* 0.418 ± 0.458*,** 0.584 ± 0.256*
Warthin tumor (n = 16) 0.511 ± 0.970* 0.861 ± 0.247* 0.652 ± 0.218* 2.206 ± 0.998* 0.745 ± 0.127*
Other benign entities (n = 4) 0.611 ± 0.211 0.809 ± 0.448* 0.898 ± 0.373 2.061 ± 2.138 0.919 ± 0.318
Non-Hodgkin lymphoma (n = 4) 0.366 ± 0.188* 0.621 ± 0.101 0.479 ± 0.223** 0.317 ± 0.292 0.342 ± 0.249*
Malignant lesions (n = 16) 1.581 ± 1.393* 0.658 ± 0.411* 2.524 ± 1.278** 2.834 ± 2.816** 1.910 ± 1.226*
Table 4     Summary of groups 
of lesions with mean L/P 
greater or lower than 1.0
L/P Lesion/parenchyma ratio; Ktrans transfer constant between blood plasma and extravascular extracel-
lular blood space (EES); Kep rate constant between EES and blood plasma (Ktrans/Ve); Ve fractional EES 
volume; Vp fractional plasma volume; AEC area of all times enhancement curve
Histology L/P Ktrans L/P Kep L/P Ve L/P Vp L/P AEC
Pleomorphic adenoma (n = 20)  < 1  < 1  > 1  < 1  < 1
Warthin tumor (n = 16)  < 1  < 1  < 1  > 1  < 1
Other benign entities (n = 4)  < 1  < 1  < 1  > 1  < 1
Non-Hodgkin lymphoma (n = 4)  < 1  < 1  < 1  < 1  < 1
Malignant lesions (n = 16)  > 1  < 1  > 1  > 1  > 1
La radiologia medica 
1 3
intravenous injection) followed by a slow washout. This 
perfusion curve reflects on quantitative DCE parameters, 
resulting in higher values of Ktrans, Kep, Vp, and AEC than, 
for example, adjacent soft tissues, when visually evaluated 
on correspondent color maps or measured by placing ROIs. 
In salivary glands, tumors cellularity (type and density), 
microarchitecture, and microcirculation are different from 
normal parenchyma, and our results demonstrated that these 
changes could be disclosed by DCE analysis. In our series, 
pleomorphic adenoma presented increased Ve and reduced 
Vp values than normal salivary parenchyma with mean L/P 
ratio values, respectively, of 1.868 and 0.418; this could be 
related to the presence of some myxoid stromal component 
inside this type of tumor and reflects the generally high val-
ues of apparent diffusion coefficient (ADC) derived by Dw 
images. On the other side, Warthin tumor due to its high 
density of cells (oncocytic epithelium and follicles contain-
ing lymphoid tissue) and microvessels presented decreased 
Ve (mean L/P ratio value 0.652) and increased Vp (2.206) 
than normal parenchyma. Lymphoproliferative lesions are 
usually composed of follicles containing very high cell den-
sity and a quite low vascularization, so reduced extracellular 
and vascular space volume brought to lower L/P Ve (0.479) 
and Vp (0.317), as expected. The low extracellular space 
volume of both Warthin tumor and lymphoma is also high-
lighted by the presence of restricted diffusion of both on Dw 
images, generally greater for lymphoma.
In our series clinically benign lesions including pleomor-
phic adenoma, Warthin tumors and other histotypes (such as 
myoepithelioma, basal cell adenoma, and oncocytoma) pre-
sented mean values of Ktrans ad AEC well lower than nor-
mal parenchyma (mean L/P ratio, respectively, of 0.485 and 
0.682) and this was just clearly evident by visually analyzing 
the color maps, other than by measuring values by ROIs. 
Malignancies, as expected due to the presence of prominent 
neovascularization, in our series show very well increased 
values of Ktrans, Vp, and AEC than normal parenchyma 
Table 5      Mean values of DCE parameters in benign and malignant 
lesions with t test significance
Except where otherwise indicated, data are mean values ± standard 
deviation
* Significant difference (< 0.05)




L/P Ktrans 0.485 ± 0.201 1.581 ± 1.393 0.001*
L/P Kep 0.587 ± 0.376 0.658 ± 0.411 0.443
L/P Ve 1.285 ± 1.147 2.524 ± 1.280 0.309
L/P Vp 1.297 ± 1.277 2.834 ± 2.816 0.006*
L/P AEC 0.682 ± 0.241 1.910 ± 1.226 0.0001*
Fig. 2  Box-and-whisker plots chart representing values of lesion/
parenchyma ratio (L/P) of DCE-MRI pharmacokinetic parameters in 
benign (blue boxes) and malignant salivary gland tumors (red boxes, 
excluding the n = 4 cases of non-Hodgkin lymphoma). The lower 
and upper hinges of the boxes denote the 25th and 75th percentiles, 
respectively. The median (50th percentile) of each distribution is 
indicated by the line. Malignant tumors presented ratio values mostly 
above the reference line of 1.0 with significant differences in mean 
values of L/P Ktrans (p = 0.001), L/P Vp (p < 0.01), and L/P AEC 
(p < 0.001)
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(corresponding mean L/P of 1.581, 2.834, and 1.910), and 
also this was just clearly visible on color maps. Tumor neo-
angiogenesis brings higher microvascular density in malig-
nancies than normal reference tissue and benign tumors; 
this reflects higher Vp. Moreover, increased microvascular 
permeability can be observed because of larger fenestrations 
in capillary vessels. Consequently, a greater amount of con-
trast medium can pass into extracellular interstitial space, 
reflecting higher Ktrans and AEC of malignant tumors [22]. 
Therefore, L/P of Ktrans and AEC were advantageous in 
differentiating malignancies from clinically benign tumors, 
as demonstrated by ROC analysis. The cutoff value for L/P 
AEC with the highest values of sensitivity and specificity 
(respectively, of 93.8 and 97.5%) was 1.038, and this appears 
significant in terms of clinical ease of use of the method. 
In fact, in our series by only examining the AEC color map 
in the majority of cases we were quite easily able to visu-
ally recognize if the lesion had a color pattern representing 
higher or lower AEC value than normal parenchyma and, 
consequently, if it appeared suspicious for malignancy, even 
without the need of drawing the two ROIs and calculating 
the ratio.
Our study presents the following limitations. First of 
all, it is a retrospective study with a relatively small cohort 
of patients and quantitatively non-homogenous histologi-
cal groups, that, however, reflect the prevalence of the dif-
ferent salivary gland tumor histotypes in the population. 
Secondly, in the process of distinguishing malignant from 
benign tumors, some problems may arise when cystic or 
necrotic areas are present inside a tumor. We have found 
that if intratumoral cystic/necrotic areas comprised less than 
about half of the tumoral surface on a given slice, the perfu-
sion curve of the inclusive ROI was still viable and quantita-
tive parameters of the non-cystic part of the tumor were not 
significantly affected. On the contrary, when larger cystic/
necrotic areas were present, the measured perfusion curve 
of the inclusive ROI was generally unreliable, so we had to 
exclude them from the analysis, if possible, to get meaning-
ful measurements of DCE parameters. In the end, when we 
faced an entirely cystic lesion, we acknowledged the per-
fusion would not be helpful, so the differential diagnosis 
should be derived by looking at conventional morphologic 
and DwI.
Moreover, during routinary clinical practice, it could 
be possible to face the presence of bilateral salivary gland 
involvement. This problem in our experience occurred 
only in the case of Warthin tumors, which usually are 
capsulated and have well-defined margins. In such a case, 
it could be hypothesized that the presence of the tumor 
itself should not alter the peritumoral salivary gland 
parenchyma, and reliable results can be obtained by cor-
relating the DCE parametric values of the lesion to those 
obtained in the morphologically normal adjacent paren-
chyma. Lastly, older and obese patients may present dys-
trophic changes and more abundant fat infiltration of the 
parotid tissue that can alter normal microcirculation (with 
Fig. 3  ROC curves of lesion/
parenchyma ratio (L/P) of 
DCE-MRI pharmacokinetic 
parameters for the differen-
tiation between malignant and 
benign salivary gland tumors. 
The area under the curve was, 
respectively, of 0.93 for L/P 
Ktrans (blue line) and 0.96 
for L/P AEC (orange line). By 
applying the cutoff L/P AEC 
value of 1.038, sensitivity and 
specificity in discriminating 
malignant from benign lesions 
were, respectively, 93.8% and 
97.5%
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a reduction in the microvessel density) and, consequently, 
pharmacokinetic measures. In such cases, we generally 
observe a decrease in values of Ktrans, Vp, and AEC, so 
benign tumors may show L/P Ktrans and AEC greater than 
1.0, leading to false positive for malignancy.
Most of the literature studies investigating the potential 
of perfusion and diffusion MR imaging in the characteriza-
tion of salivary gland tumors [10–15] described different 
imaging post-processing methods that are often not readily 
available for clinical routine. On the other hand, software 
applications using extended Tofts model [19] for perme-
ability analysis of MR images nowadays are quite popular 
and generally easy to handle. They also are usually capa-
ble of generating “fancy” pixel-by-pixel color maps rep-
resenting quantitative parameters whose variability, when 
taken for their absolute value, may lead to inconclusive 
results. Our study, through the introduction of the ratio 
between the tumor and the normal parenchyma, provided a 
clinically feasible method that appeared to bypass the vari-
ability issues of the measures, present indications on how 
to use these color maps effectively, and introduce potential 
biomarkers easy to estimate and understand.
Conclusion
In conclusion, our study proved how the evaluation of pixel-
by-pixel DCE-MR parametric maps could be useful for rec-
ognizing the principal types of salivary gland tumors by the 
comparison between the lesion and the normal parenchyma. 
Moreover, the lesion/parenchyma ratio of the area of all 
times enhancement curve seems a very valuable biomarker 
for differentiating benign from malignant tumors. In our 
opinion, this type of analysis should always be included in 
the setting of a multiparametric imaging approach for these 
tumors.
Fig. 4  68-year-old man and 70-year-old woman, respectively, with 
basal cell adenoma (a, c) and basal cell adenocarcinoma (b, d) of the 
left parotid gland. Comparison of derived DCE-MRI data. In a and 
b are represented color-coded maps of the area of all times enhance-
ment curve (AEC) with corresponding ROIs of the lesion (white 
arrows, blue line) and normal contralateral parenchyma (white arrow-
heads, orange line). In c and d are displayed the time–signal intensity 
curves of drawn ROIs (blue line representing lesion and orange line 
representing parenchyma). Morphology of tumor enhancement curve 
is similar in the two cases (early wash-in followed by washout); how-
ever, the malignant tumor curve sits well above the standard paren-
chyma curve at all times. In these cases, the calculated lesion/paren-
chyma ratios of AEC were 0.868 for the adenoma and 3.392 for the 
adenocarcinoma
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